Taysha Gene Therapies Inc. Insider Trading

TSHA

Last 12 months

Insiders sold $6.66M and bought nothing on the open market.

46% of the selling was scheduled in advance under 10b5-1 plans. President and Head of R&D Sukumar Nagendran sold $1.7M on Dec 1, 2025, 27% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2023.

Net open-market

−$6.66M

0 buys · 8 sales

Under a 10b5-1 plan

46%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Aug 2023

Aug 16, 2023

Get an email when TSHA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 10	Sukumar Nagendran President and Head of R&D	Sold10b5-1 plan	200,000	$6.24	$1.25M	18%	Form 4
Apr 10	Sukumar Nagendran President and Head of R&D	Sold10b5-1 plan	200,000	$4.46	892K	15%	Form 4
Feb 4	Kamran Alam Chief Financial Officer	SoldNo plan	1,655	$4.52	7K	0.1%	Form 4
Jan 23 – 26	Kamran Alam Chief Financial Officer	SoldNo plan 2 parts	102,817	$4.72 average	485K	6.6%	Form 4
Jan 23 – 26	Sukumar Nagendran President and Head of R&D	SoldNo plan 2 parts	116,050	$4.72 average	547K	8.1%	Form 4
Jan 23 – 26	Sean P. Nolan Chief Executive Officer	SoldNo plan 2 parts	178,101	$4.72 average	840K	3.9%	Form 4
Jan 12	Sukumar Nagendran President and Head of R&D	Sold10b5-1 plan	200,000	$4.71	942K	12%	Form 4
Nov 28, 2025 – Dec 1, 2025	Sukumar Nagendran President and Head of R&D	SoldNo plan 2 parts	370,172	$4.58 average	$1.7M	27%	Form 4
Sep 10, 2025	Sukumar Nagendran President and Head of R&D	Sold10b5-1 plan	200,000	$3.23	646K	17%	Form 4
Aug 21, 2025	Sukumar Nagendran President and Head of R&D	SoldNo plan	57,054	$2.85	163K	4.7%	Form 4
Aug 21, 2025	Kamran Alam Chief Financial Officer	SoldNo plan	54,491	$2.85	155K	4.4%	Form 4
May 30, 2025	Paul B Manning Large holder	Bought	750,000	$2.75	$2.06M	36%	Form 4

Jul 1010b5-1 plan
Sukumar Nagendran
President and Head of R&D · sold 200,000 at $6.24
$1.25M
18% of stake
Apr 1010b5-1 plan
Sukumar Nagendran
President and Head of R&D · sold 200,000 at $4.46
892K
15% of stake
Feb 4No plan
Kamran Alam
Chief Financial Officer · sold 1,655 at $4.52
7K
0.1% of stake
Jan 23 – 26No plan
Kamran Alam
Chief Financial Officer · sold 102,817 at avg $4.72
485K
6.6% of stake
Jan 23 – 26No plan
Sukumar Nagendran
President and Head of R&D · sold 116,050 at avg $4.72
547K
8.1% of stake
Jan 23 – 26No plan
Sean P. Nolan
Chief Executive Officer · sold 178,101 at avg $4.72
840K
3.9% of stake
Jan 1210b5-1 plan
Sukumar Nagendran
President and Head of R&D · sold 200,000 at $4.71
942K
12% of stake
Nov 28, 2025 – Dec 1, 2025No plan
Sukumar Nagendran
President and Head of R&D · sold 370,172 at avg $4.58
$1.7M
27% of stake
Sep 10, 202510b5-1 plan
Sukumar Nagendran
President and Head of R&D · sold 200,000 at $3.23
646K
17% of stake
Aug 21, 2025No plan
Sukumar Nagendran
President and Head of R&D · sold 57,054 at $2.85
163K
4.7% of stake
Aug 21, 2025No plan
Kamran Alam
Chief Financial Officer · sold 54,491 at $2.85
155K
4.4% of stake
May 30, 2025
Paul B Manning
Large holder · bought 750,000 at $2.75
$2.06M
36% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TSHA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TSHA

CompareIntrinsic value

CGONCG Oncology, Inc.

$67.71+5.70%40

DBVTDBV Technologies S.A.

$9.94-1.68%10

FATEFate Therapeutics Inc.

$2.09+2.45%10

PRMEPrime Medicine Inc.

$4.97+9.23%0

OCGNOcugen Inc.

$0.88+17.45%40

ZEOXZeo Scientifix Inc.

$0.97+0.00%25

CRISCuris Inc.

$1.11+56.34%25

DYAIDyadic International Inc.

$0.37+1.86%36

Held by ETFs

TSHA is in 35 US ETFs. The largest of them, with TSHA's weight in each:

Spot a number that looks wrong? Check it in TSHA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TSHA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.